·   Tirzepatide has completed US-DMF filing.

·   Leuprorelin acetate has passed registration verification.

·   The production bases for Liraglutide, Semaglutide, Tirzepatide, and Oxytocin have obtained WC certification.

·   The Hubei JXBio A15 workshop has been completed and put into operation.

·   The pilot-scale base project jointly submitted by JYMed and the Pingshan Center has been included in the project funding list.

·   Semaglutide and Liraglutide have been awarded the Guangdong Provincial High-Quality and High-Tech Product Certificate.

·   Hubei JXBio has passed the Oxytocin registration site inspection and GMP compliance inspection.

·   Terlipressin Injection, Carbetocin Injection, and Terlipressin for Injection (a single variety) have obtained registration approvals or consistency evaluation/ supplementary approvals.

·   Multiple APIs and formulations, such as Octreotide Acetate, Desmopressin, Liraglutide, Degarelix Acetate, Bivalirudin, Semaglutide, and others, have obtained domestic and international registration approvals or DMF numbers, and have passed FDA technical reviews or registration inspections.

·   Bivalirudin API has been approved.

·   Terlipressin Injection has obtained a production license.

·   Liraglutide and Tirzepatide Injections have been approved for clinical use.

·   On May 18, 2019, the first phase of the first phase of the novel peptide APIs industrial park of Hubei JXBio Co., Ltd. was officially trial-produced.

·   In 2018, the first class I innovative drug, K(D)PT Acetate, was obtained for 

     clinical approval. 

·   The Peptide Products Division once again passed the US FDA on-site audit.

· “Guangdong Province Synthetic Peptide Innovative Drug Engineering 

     Technology Research Center” was approved.

·   For the first time, the Peptide Products Division successfully passed the US FDA on-site quality audit.

·   In 2016, the Peptide Products Division was audited by suppliers of Fresenius 

     Kabi and Pfizer in the United States and entered its supplier list. 

·   On November 27th, Hubei JXBio Pharmaceutical Co., Ltd. started the 

     foundation of the novel peptide APIs industrial park, which marked that 

     JYMed has achieved a new leap in the field of peptide industrialization.

·   The subsidiary company, Hubei JXBio Pharmaceutical Co., Ltd., was established

      in Hubei.

 ·   JYMed relocated officiallyto the Shenzhen Pingshan Bio-accelerator Industry 

      Park.

·   The company established a strategic partnership with ROCHEM, and the APIs entered the mainstream markets in Europe and America.

·   In 2013, the subsidiary company, Shenzhen JXBio Pharmaceutical Co.,Ltd.,was established in Shenzhen.

·   The company was certified as a National high-tech enterprise.

·   The application of the first medicine ANDA to NMPA was completed.

·   The company was certified as a high-tech enterprise in Shenzhen

·   JYMed peptide R&D center was started up in Shenzhen Nanshan High-tech District Bio-Incubator Base.

·   In April 2009, Shenzhen JYMed Technology Co.,Ltd. was founded.